A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or
metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT),
maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of
SI-B003.
In the phase Ib study, the safety and tolerability of SI-B003 in specific tumors will be
further investigated by selecting multiple doses based on the results of phase Ia study
or/and the fixed-dose administration method with the closest exposure level, and recommended
phase II dose (RP2D) for phase II clinical studies will be determined.